Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease
Open Access
- 22 February 2024
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (5) , 528.e1-528.e12
Abstract
No abstract availableKeywords
Funding Information
- Incyte Corp
This publication has 18 references indexed in Scilit:
- Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjectsCancer Chemotherapy and Pharmacology, 2019
- Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant PatientsTransplantation and Cellular Therapy, 2017
- Acute Graft Versus Host Disease: A Comprehensive ReviewAnticancer Research, 2017
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2015
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Pediatric Blood & Cancer, 2015
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseBlood, 2014
- Steroid-Refractory Acute GVHD: Predictors and OutcomesAdvances in Hematology, 2011
- Graft-versus-host diseaseThe Lancet, 2009
- Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and ChildrenClinical Pharmacokinetics, 2006
- MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoringComputers in Biology and Medicine, 1992